Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors

International Journal of Gastrointestinal Cancer

Volumn 32, Issue 2-3, 2002, Pages 63-72

  Farrow, Buckminster ^a   Thomas, Robert P ^a   Wang, Xiao Fu ^a   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Apoptosis; Bad; Pancreatic cancer; Protein kinase C; TRAIL

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; BRYOSTATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BAD; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0038308404     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:32:2-3:63     Document Type: Article

References (55)

1. Tominaga S, Kuroishi T. Epidemiology of pancreatic cancer. Semin Surg Oncol 1998;15:3-7.
2. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-636.
3. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF, Jr. Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175-182.
4. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661-665.
5. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem 1995;270:28,495-28,498.
6. Trauzold A, Wermann H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001;20:4258-4269.
7. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997;32:284-293.
8. Philip PA, Rea D, Thavasu P, et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993;85:1812-1818.
9. Propper DJ, Macaulay V, O'Byrne KJ, et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 1998;78:1337-1341.
10. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001;23:251-258.
11. Friess H, Lu Z, Andren-Sandberg A, et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;228:780-787.
12. Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 2002;132:127-134.
13. Hernandez A, Wang QD, Schwartz SA, Evers BM. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg 2001;5:56-65.
14. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-554.
15. Wang XM, Wang X, Li J, Evers BM. Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Ann Surg 1998;227:922-931.
16. Goekjian PG, Jirousek MR. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr Med Chem 1999;6:877-903.
17. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:1-11.
18. Kang CD, Yoo SD, Hwang BW, et al. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk Res 2000;24:527-534.
19. Baillie G, MacKenzie SJ, Houslay MD. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 2001;60:1100-1111.
20. Nichols RA, Haycock JW, Wang JK, Greengard P. Phorbol ester enhancement of neurotransmitter release from rat brain synaptosomes. J Neurochem 1987;48:615-621.
21. Gomez-Angelats M, Bortner CD, Cidlowski JA. Protein kinase C (PKC) inhibits fas receptor-induced apoptosis through modulation of the loss of K+ and cell shrinkage. A role for PKC upstream of caspases. J Biol Chem 2000;275:19,609-19,619.
22. Schaufelberger DE, Koleck MP, Beutler JA, et al. The larges-cale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J Nat Prod 1991;54:1265-1270.
23. Pluda JM, Cheson BD, Phillips PH. Clinical trials referral resource. Clinical trials using bryostatin-1. Oncology (Huntingt) 1996;10:740-742.
24. Dekker LV, Parker PJ. Protein kinase C - a question of specificity. Trends Biochem Sci 1994;19:73-77.
25. Way KJ, Chou E, King GL. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000;21:181-187.
26. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994;199:93-98.
27. Ishino K, Fukazawa H, Shikano M, Ohba M, Kuroki T, Uehara Y. Enhancement of anchorage-independent growth of human pancreatic carcinoma MIA PaCa-2 cells by signaling from protein kinase C to mitogen-activated protein kinase. Mol Carcinog 2002;34:180-186.
28. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001;13:863-875.
29. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999;19:5308-5315.
30. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-6599.
31. Hansen JB, Petersen RK, Jorgensen C, Kristiansen K. Deregulated MAPK activity prevents adipocyte differentiation of fibroblasts lacking the retinoblastoma protein. J Biol Chem 2002;277:26,335-26,339.
32. Lee JC, Kassis S, Kumar S, BadgerA, Adams JL. p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 1999;82:389-397.
33. Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 2002;1589:311-316.
34. Assefa Z, Valius M, Vantus T, Agostinis P, Merlevede W, Vandenheede JR. JNK/SAPK activation by platelet-derived growth factor in A431 cells requires both the phospholipase C-gamma and the phosphatidylinositol 3-kinase signaling pathways of the receptor. Biochem Biophys Res Commun 1999;261:641-645.
35. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 1999;15:793-802.
36. Slater SJ, Kelly MB, Taddeo FJ, Rubin E, Stubbs CD. Evidence for discrete diacylglycerol and phorbol ester activator sites on protein kinase C. Differences in effects of 1-alkanol inhibition, activation by phosphatidylethanolamine and calcium chelation. J Biol Chem 1994;269:17,160-17,165.
37. Aihara H, Asaoka Y, Yoshida K, Nishizuka Y. Sustained activation of protein kinase C is essential to HL-60 cell differentiation to macrophage. Proc Nat Acad Sci USA 1991;88:11,062-11,066.
38. Parker PJ. Inhibition of protein kinase C - do we, can we, and should we? Pharmacol Ther 1999;82:263-267.
39. Takei T, Han O, Ikeda M, Male P, Mills I, Sumpio BE. Cyclic strain stimulates isoform-specific PKC activation and translocation in cultured human keratinocytes. J Cell Biochem 1997;67:327-337.
40. Bamberger AM, Bamberger CM, Wald M, Jensen K, Schulte HM. PKC isoenzyme expression and cellular responses to phorbol ester in JEG-3 choriocarcinoma cells. Endocrine 1997;6:111-116.
41. Chang ZL, Beezhold DH. Protein kinase C activation in human monocytes: regulation of PKC isoforms. Immunology 1993;80:360-366.
42. Saijo N, Nishio K,Yoshida M. Overcoming drug resistance in lung cancer. Oncology (Huntingt) 1998;12:87-89.
43. Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225-3236.
44. Ottilie S, Diaz JL, Horne W, et al. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins. J Biol Chem 1997;272:30,866-30,872.
45. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-291.
46. Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999;56:73-82.
47. Vukosavic S, Dubois-Dauphin M, Romero N, Przedborski S. Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999;73:2460-2468.
48. Moriishi K, Koura M, Matsuura Y. Induction of Bad-mediated apoptosis by Sindbis virus infection: involvement of pro-survival members of the Bcl-2 family. Virology 2002;292:258-271.
49. Kondo S, Shinomura Y, Kanayama S, et al. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells. Oncogene 1998;17:2585-2591.
50. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002;95:941-945.
51. Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001;188:98-105.
52. Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 2001;18:241-247.
53. He Q, Lee DI, Rong R, et al. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 2002;21:2623-2633.
54. Higuchi H, Bronk SF, Takikawa Y, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001;276:38, 610-38,618.
55. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149-7155.